Moomoo AIのまとめ
Vivos Therapeutics, a medical technology company, reported financial results for the quarter ended June 30, 2024. Total revenue increased by $659,000 to $4.054 million compared to the same period last year, driven by a $429,000 rise in product revenue and a $230,000 increase in service revenue. The company's gross profit improved to $2.651 million, with a gross margin of 65%, up from 62% in the previous year. Operating expenses decreased by $2.029 million, primarily due to a $1.755 million reduction in general and administrative expenses. The company's net loss narrowed to $1.930 million from $5.528 million in the prior-year quarter. Vivos Therapeutics also highlighted its strategic alliance with Rebis Health Holdings and a management services agreement with V-CO Investors LLC, aimed at expanding its marketing and distribution model. The company's cash and cash equivalents stood at $6.903 million, with management actively exploring additional financing options to support operations and strategic objectives. Despite progress in remediation efforts, the company acknowledged an existing material weakness in internal control over financial reporting and is working towards full remediation.
Vivos Therapeutics, a medical technology company, reported financial results for the quarter ended June 30, 2024. Total revenue increased by $659,000 to $4.054 million compared to the same period last year, driven by a $429,000 rise in product revenue and a $230,000 increase in service revenue. The company's gross profit improved to $2.651 million, with a gross margin of 65%, up from 62% in the previous year. Operating expenses decreased by $2.029 million, primarily due to a $1.755 million reduction in general and administrative expenses. The company's net loss narrowed to $1.930 million from $5.528 million in the prior-year quarter. Vivos Therapeutics also highlighted its strategic alliance with Rebis Health Holdings and a management services agreement with V-CO Investors LLC, aimed at expanding its marketing and distribution model. The company's cash and cash equivalents stood at $6.903 million, with management actively exploring additional financing options to support operations and strategic objectives. Despite progress in remediation efforts, the company acknowledged an existing material weakness in internal control over financial reporting and is working towards full remediation.
医療関連テクノロジー企業のVivos Therapeuticsは、2024年6月30日終了の四半期の財務結果を発表しました。総売上高は、製品売上高が$ 429,000増加し、サービス売上高が$ 230,000増加したことにより、前年同期比で$ 659,000増加して$ 4,054,000に達しました。同社の粗利益は$ 2,651,000に改善され、粗利率は前年の62％から65％に上昇しました。営業費用は$ 2,029,000減少し、主に一般管理費用の$ 1,755,000削減が原因です。同社の純損失は、前年同期の$ 5,528,000から$ 1,930,000に縮小しました。Vivos The...すべて展開
医療関連テクノロジー企業のVivos Therapeuticsは、2024年6月30日終了の四半期の財務結果を発表しました。総売上高は、製品売上高が$ 429,000増加し、サービス売上高が$ 230,000増加したことにより、前年同期比で$ 659,000増加して$ 4,054,000に達しました。同社の粗利益は$ 2,651,000に改善され、粗利率は前年の62％から65％に上昇しました。営業費用は$ 2,029,000減少し、主に一般管理費用の$ 1,755,000削減が原因です。同社の純損失は、前年同期の$ 5,528,000から$ 1,930,000に縮小しました。Vivos Therapeuticsは、Rebis Health Holdingsとの戦略的提携とV-CO Investors LLCとの管理サービス契約にも注目し、そのマーケティングおよび販売モデルの拡大を目指しています。現金及び現金同等物は$ 6,903,000であり、経営陣は積極的に追加の資金調達オプションを探索し、業務および戦略目標をサポートするための支援をしています。問題の緩和に進展があったにもかかわらず、会社は財務報告における内部統制上の重大な問題を認め、完全な問題解決に向けて取り組んでいます。
役に立った
役に立たない